Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P van Meerbeeck

Showing results (171-180 of 250) with videos related to

Pageof 25
Sort By:
Cancers|January 20, 2021
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3Elly Marcq, Jonas R M Van Audenaerde, Jorrit De Waele, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|March 6, 2018
Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available dataFrance Vrijens, Cindy De Gendt, Leen Verleye, et al.
American Journal of Respiratory and Critical Care Medicine|January 16, 2010
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Joël Thimpont, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)Rabab M Gaafar, Veerle F Surmont, Giorgio V Scagliotti, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2026
Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and RecommendationsKathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, et al.
The European Respiratory Journal|December 25, 2014
Estimation of post-operative forced expiratory volume by functional respiratory imagingAnnelies Janssens, Wim Vos, Cedric Van Holsbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of CanadaJan P van Meerbeeck, Rabab Gaafar, Christian Manegold, et al.
Oncoimmunology|February 16, 2017
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesotheliomaElly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, et al.
Cytotherapy|August 21, 2018
An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccinationE Brabants, K Heyns, S De Smet, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Pageof 25

Showing results (171-180 of 250) with videos related to

Sort By:
Pageof 25
Cancers|January 20, 2021
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3Elly Marcq, Jonas R M Van Audenaerde, Jorrit De Waele, et al.
International Journal for Quality in Health Care : Journal of the International Society for Quality in Health Care|March 6, 2018
Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available dataFrance Vrijens, Cindy De Gendt, Leen Verleye, et al.
American Journal of Respiratory and Critical Care Medicine|January 16, 2010
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesotheliomaKevin Hollevoet, Kristiaan Nackaerts, Joël Thimpont, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)Rabab M Gaafar, Veerle F Surmont, Giorgio V Scagliotti, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2026
Multi-omic screening for pleural mesothelioma in Asbestos-Exposed Populations: A literature review and RecommendationsKathleen Zwijsen, Ellen Heirwegh, Eline Schillebeeckx, et al.
The European Respiratory Journal|December 25, 2014
Estimation of post-operative forced expiratory volume by functional respiratory imagingAnnelies Janssens, Wim Vos, Cedric Van Holsbeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of CanadaJan P van Meerbeeck, Rabab Gaafar, Christian Manegold, et al.
Oncoimmunology|February 16, 2017
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesotheliomaElly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, et al.
Cytotherapy|August 21, 2018
An accelerated, clinical-grade protocol to generate high yields of type 1-polarizing messenger RNA-loaded dendritic cells for cancer vaccinationE Brabants, K Heyns, S De Smet, et al.
Critical Reviews in Oncology/Hematology|April 30, 2015
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysisGiuseppe Bronte, Christian Rolfo, Francesco Passiglia, et al.
Pageof 25